Jason G. Sagert

Person

San Mateo, CA, US

People

Patents Grantslast 30 patents

Information Patent Grant
Masked chimeric antigen receptor specific to tyrosine-protein kinas...
- Patent number 11,926,676
- Issue date Mar 12, 2024
- CRISPR THERAPEUTICS AG
- Jason Sagert
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Activatable antibodies that bind epidermal growth factor receptor a...
- Patent number 11,890,354
- Issue date Feb 6, 2024
- CytomX Therapeutics, Inc.
- Henry Bernard Lowman
- G01 - MEASURING TESTING
Information Patent Grant
Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 ant...
- Patent number 11,802,158
- Issue date Oct 31, 2023
- Cytomx Therapeutics, Inc.
- Bryan Allen Irving
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Anti-CD166 antibodies, activatable anti-CD166 antibodies, and metho...
- Patent number 11,753,466
- Issue date Sep 12, 2023
- CytomX Therapeutics, Inc.
- James William West
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Gene-edited natural killer cells
- Patent number 11,591,381
- Issue date Feb 28, 2023
- CRISPR THERAPEUTICS AG
- Valentin Sluch
- C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information Patent Grant
Matrix metalloprotease-cleavable and serine protease-cleavable subs...
- Patent number 11,548,944
- Issue date Jan 10, 2023
- CytomX Therapeutics, Inc.
- Stephen James Moore
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Matrix metalloprotease-cleavable and serine protease-cleavable subs...
- Patent number 11,548,943
- Issue date Jan 10, 2023
- CytomX Therapeutics, Inc.
- Stephen James Moore
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Matrix metalloprotease-cleavable and serine protease-cleavable subs...
- Patent number 11,472,875
- Issue date Oct 18, 2022
- CytomX Therapeutics, Inc.
- Stephen James Moore
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Gene-edited natural killer cells
- Patent number 11,459,372
- Issue date Oct 4, 2022
- CRISPR THERAPEUTICS AG
- Valentin Sluch
- C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information Patent Grant
Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods...
- Patent number 11,267,896
- Issue date Mar 8, 2022
- CytomX Therapeutics, Inc.
- Jason Gary Sagert
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods...
- Patent number 11,174,316
- Issue date Nov 16, 2021
- CytomX Therapeutics, Inc.
- James William West
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Matrix metalloprotease-cleavable and serine protease-cleavable subs...
- Patent number 11,046,759
- Issue date Jun 29, 2021
- CytomX Therapeutics, Inc.
- Stephen James Moore
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Methods for manufacturing activatable binding polypeptides comprisi...
- Patent number 11,028,162
- Issue date Jun 8, 2021
- The Regents of the University of California
- Patrick Sean Daugherty
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Methods of treatment using activatable anti-EGFR antibodies
- Patent number 10,875,913
- Issue date Dec 29, 2020
- CytomX Therapeutics, Inc.
- Nancy Elizabeth Stagliano
- G01 - MEASURING TESTING
Information Patent Grant
Anti-CD166 antibodies, activatable anti-CD166 antibodies, and metho...
- Patent number 10,745,481
- Issue date Aug 18, 2020
- CytomX Therapeutics, Inc.
- James William West
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Activatable antibodies that bind epidermal growth factor receptor a...
- Patent number 10,709,799
- Issue date Jul 14, 2020
- CytomX Therapeutics, Inc.
- Henry Bernard Lowman
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 ant...
- Patent number 10,669,337
- Issue date Jun 2, 2020
- CytomX Therapeutics, Inc.
- Bryan Allen Irving
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods...
- Patent number 10,669,339
- Issue date Jun 2, 2020
- CytomX Therapeutics, Inc.
- James William West
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Activatable antibodies that bind interleukin-6 receptor and methods...
- Patent number 10,611,845
- Issue date Apr 7, 2020
- CytomX Therapeutics, Inc.
- James William West
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Anti-CD166 antibodies, activatable anti-CD166 antibodies, and metho...
- Patent number 10,577,420
- Issue date Mar 3, 2020
- CytomX Therapeutics, Inc.
- James William West
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Cleavage-activatable interferon-alpha proprotein
- Patent number 10,513,549
- Issue date Dec 24, 2019
- CytomX Therapeutics, Inc.
- Nancy E. Stagliano
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods...
- Patent number 10,336,824
- Issue date Jul 2, 2019
- CytomX Therapeutics, Inc.
- James William West
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-...
- Patent number 10,301,380
- Issue date May 28, 2019
- CytomX Therapeutics, Inc.
- James William West
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and metho...
- Patent number 10,233,244
- Issue date Mar 19, 2019
- CytomX Therapeutics, Inc.
- Jason Gary Sagert
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods...
- Patent number 10,179,817
- Issue date Jan 15, 2019
- CytomX Therapeutics, Inc.
- Jason Gary Sagert
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Modified antibody containing the cleavable peptide with the amino a...
- Patent number 10,118,961
- Issue date Nov 6, 2018
- CytomX Therapeutics, Inc.
- Nancy E. Stagliano
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Activatable binding polypeptides and methods of identification and...
- Patent number 10,077,300
- Issue date Sep 18, 2018
- The Regents of the University of California
- Patrick Sean Daugherty
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Anti-EGFR activatable antibodies
- Patent number 10,059,762
- Issue date Aug 28, 2018
- CytomX Therapeutics, Inc.
- Nancy Elizabeth Stagliano
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Activatable antibodies that bind epidermal growth factor receptor a...
- Patent number 9,889,211
- Issue date Feb 13, 2018
- CytomX Therapeutics, Inc.
- Henry Bernard Lowman
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-...
- Patent number 9,688,748
- Issue date Jun 27, 2017
- CytomX Therapeutics, Inc.
- James William West
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Patents Applicationslast 30 patents

Information Patent Application
BISPECIFIC ANTI-CD3 ANTIBODIES, BISPECIFIC ACTIVATABLE ANTI-CD3 ANT...
- Publication number 20240084010
- Publication date Mar 14, 2024
- CytomX Therapeutics, Inc.
- Bryan Allen Irving
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTI-CD166 ANTIBODIES, ACTIVATABLE ANTI-CD166 ANTIBODIES, AND METHO...
- Publication number 20240076374
- Publication date Mar 7, 2024
- CytomX Therapeutics, Inc.
- James William West
- C07 - ORGANIC CHEMISTRY
Information Patent Application
GENE-EDITED NATURAL KILLER CELLS
- Publication number 20230227532
- Publication date Jul 20, 2023
- CRISPR Therapeutics AG
- Valentin SLUCH
- C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information Patent Application
GENETICALLY ENGINEERED T CELLS EXPRESSING BCMA-SPECIFIC CHIMERIC AN...
- Publication number 20230220059
- Publication date Jul 13, 2023
- CRISPR Therapeutics AG
- Jonathan Alexander TERRETT
- C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information Patent Application
MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE-CLEAVABLE SUBS...
- Publication number 20230212283
- Publication date Jul 6, 2023
- CytomX Therapeutics, Inc.
- Stephen James Moore
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
PROPROTEINS AND METHODS OF USE THEREOF
- Publication number 20230183308
- Publication date Jun 15, 2023
- CytomX Therapeutics, Inc.
- Nancy E. Stagliano
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
MASK PEPTIDES AND MASKED ANTI-PTK7 ANTIBODIES COMPRISING SUCH
- Publication number 20230181750
- Publication date Jun 15, 2023
- CRISPR Therapeutics AG
- Jason Sagert
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
GENE-EDITED NATURAL KILLER CELLS
- Publication number 20230130564
- Publication date Apr 27, 2023
- CRISPR Therapeutics AG
- Valentin SLUCH
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
PROPROTEINS AND METHODS OF USE THEREOF
- Publication number 20230035290
- Publication date Feb 2, 2023
- CytomX Therapeutics, Inc.
- Nancy E. Stagliano
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE-CLEAVABLE SUBS...
- Publication number 20230021301
- Publication date Jan 19, 2023
- CytomX Therapeutics, Inc.
- Stephen James Moore
- C07 - ORGANIC CHEMISTRY
Information Patent Application
MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE-CLEAVABLE SUBS...
- Publication number 20220380453
- Publication date Dec 1, 2022
- CytomX Therapeutics, Inc.
- Stephen James Moore
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTI-CD71 ANTIBODIES, ACTIVATABLE ANTI-CD71 ANTIBODIES, AND METHODS...
- Publication number 20220306759
- Publication date Sep 29, 2022
- CytomX Therapeutics, Inc.
- Jason Gary Sagert
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTI-PDL1 ANTIBODIES, ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS...
- Publication number 20220298245
- Publication date Sep 22, 2022
- CytomX Therapeutics, Inc.
- James William West
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ANTI-CD33 IMMUNE CELL CANCER THERAPY
- Publication number 20220226375
- Publication date Jul 21, 2022
- CRISPR Therapeutics AG
- Jonathan Alexander Terrett
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CANCER TREATMENT USING CD38 INHIBITOR AND/OR LENALIDOMIDE AND T-CEL...
- Publication number 20220202859
- Publication date Jun 30, 2022
- CRISPR Therapeutics AG
- Jonathan Alexander TERRETT
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CO-USE OF LENALIDOMIDE WITH CAR-T CELLS
- Publication number 20220193134
- Publication date Jun 23, 2022
- CRISPR Therapeutics AG
- Henia DAR
- C07 - ORGANIC CHEMISTRY
Information Patent Application
Activatable Binding Polypeptides and Methods of Identification and...
- Publication number 20220098294
- Publication date Mar 31, 2022
- The Regents of the University of California
- Patrick Sean Daugherty
- C07 - ORGANIC CHEMISTRY
Information Patent Application
EPCAM ANTIBODIES, ACTIVATABLE ANTIBODIES, AND IMMUNOCONJUGATES, AND...
- Publication number 20210403594
- Publication date Dec 30, 2021
- ImmunoGen, Inc.
- Yimao LIU
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTI-CD70 ANTIBODIES AND USES THEREOF
- Publication number 20210380707
- Publication date Dec 9, 2021
- CRISPR Therapeutics AG
- Jason Sagert
- G01 - MEASURING TESTING
Information Patent Application
GENETICALLY ENGINEERED CAR T CELLS THAT SECRET INTERLEUKIN-12 AND T...
- Publication number 20210363212
- Publication date Nov 25, 2021
- CRISPR Therapeutics AG
- Mohammed Ghonime
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE-CLEAVABLE SUBS...
- Publication number 20210355208
- Publication date Nov 18, 2021
- CytomX Therapeutics, Inc.
- Stephen James Moore
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
MASKED CHIMERIC ANTIGEN RECEPTOR SPECIFIC TO TYROSINE-PROTEIN KINAS...
- Publication number 20210347913
- Publication date Nov 11, 2021
- CRISPR Therapeutics AG
- Jason Sagert
- C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information Patent Application
MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE-CLEAVABLE SUBS...
- Publication number 20210347886
- Publication date Nov 11, 2021
- CytomX Therapeutics, Inc.
- Stephen James Moore
- C07 - ORGANIC CHEMISTRY
Information Patent Application
ANTI-PTK7 IMMUNE CELL CANCER THERAPY
- Publication number 20210290678
- Publication date Sep 23, 2021
- CRISPR Therapeutics AG
- Jonathan Alexander Terrett
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTI-LIV1 IMMUNE CELL CANCER THERAPY
- Publication number 20210292429
- Publication date Sep 23, 2021
- CRISPR Therapeutics AG
- Jonathan Alexander Terrett
- C07 - ORGANIC CHEMISTRY
Information Patent Application
MODIFIED ANTIBODY COMPOSITIONS, METHODS OF MAKING AND USING THEREOF
- Publication number 20210284721
- Publication date Sep 16, 2021
- CytomX Therapeutics, Inc.
- Nancy Elizabeth Stagliano
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
BISPECIFIC ANTI-CD3 ANTIBODIES, BISPECIFIC ACTIVATABLE ANTI-CD3 ANT...
- Publication number 20210047406
- Publication date Feb 18, 2021
- CytomX Therapeutics, Inc.
- Bryan Allen Irving
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ACTIVATABLE ANTIBODIES THAT BIND EPIDERMAL GROWTH FACTOR RECEPTOR A...
- Publication number 20210023243
- Publication date Jan 28, 2021
- CytomX Therapeutics, Inc.
- Henry Bernard Lowman
- G01 - MEASURING TESTING
Information Patent Application
SYSTEMS AND METHODS FOR QUANTITATIVE PHARMACOLOGICAL MODELING OF AC...
- Publication number 20210020264
- Publication date Jan 21, 2021
- CytomX Therapeutics, Inc.
- Mark Anthony Stroh
Information Patent Application
ACTIVATABLE ANTIBODIES THAT BIND INTERLEUKIN-6 RECEPTOR AND METHODS...
- Publication number 20200339694
- Publication date Oct 29, 2020
- CytomX Therapeutics, Inc.
- James William West
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Jason G. Sagert

Person

Patents Grantslast 30 patents

Masked chimeric antigen receptor specific to tyrosine-protein kinas...

Activatable antibodies that bind epidermal growth factor receptor a...

Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 ant...

Anti-CD166 antibodies, activatable anti-CD166 antibodies, and metho...

Gene-edited natural killer cells

Matrix metalloprotease-cleavable and serine protease-cleavable subs...

Matrix metalloprotease-cleavable and serine protease-cleavable subs...

Matrix metalloprotease-cleavable and serine protease-cleavable subs...

Gene-edited natural killer cells

Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods...

Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods...

Matrix metalloprotease-cleavable and serine protease-cleavable subs...

Methods for manufacturing activatable binding polypeptides comprisi...

Methods of treatment using activatable anti-EGFR antibodies

Anti-CD166 antibodies, activatable anti-CD166 antibodies, and metho...

Activatable antibodies that bind epidermal growth factor receptor a...

Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 ant...

Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods...

Activatable antibodies that bind interleukin-6 receptor and methods...

Anti-CD166 antibodies, activatable anti-CD166 antibodies, and metho...

Cleavage-activatable interferon-alpha proprotein

Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods...

Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-...

Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and metho...

Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods...

Modified antibody containing the cleavable peptide with the amino a...

Activatable binding polypeptides and methods of identification and...

Anti-EGFR activatable antibodies

Activatable antibodies that bind epidermal growth factor receptor a...

Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-...

Patents Applicationslast 30 patents

BISPECIFIC ANTI-CD3 ANTIBODIES, BISPECIFIC ACTIVATABLE ANTI-CD3 ANT...

ANTI-CD166 ANTIBODIES, ACTIVATABLE ANTI-CD166 ANTIBODIES, AND METHO...

GENE-EDITED NATURAL KILLER CELLS

GENETICALLY ENGINEERED T CELLS EXPRESSING BCMA-SPECIFIC CHIMERIC AN...

MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE-CLEAVABLE SUBS...

PROPROTEINS AND METHODS OF USE THEREOF

MASK PEPTIDES AND MASKED ANTI-PTK7 ANTIBODIES COMPRISING SUCH

GENE-EDITED NATURAL KILLER CELLS

PROPROTEINS AND METHODS OF USE THEREOF

MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE-CLEAVABLE SUBS...

MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE-CLEAVABLE SUBS...

ANTI-CD71 ANTIBODIES, ACTIVATABLE ANTI-CD71 ANTIBODIES, AND METHODS...

ANTI-PDL1 ANTIBODIES, ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS...

ANTI-CD33 IMMUNE CELL CANCER THERAPY

CANCER TREATMENT USING CD38 INHIBITOR AND/OR LENALIDOMIDE AND T-CEL...

CO-USE OF LENALIDOMIDE WITH CAR-T CELLS

Activatable Binding Polypeptides and Methods of Identification and...

EPCAM ANTIBODIES, ACTIVATABLE ANTIBODIES, AND IMMUNOCONJUGATES, AND...

ANTI-CD70 ANTIBODIES AND USES THEREOF

GENETICALLY ENGINEERED CAR T CELLS THAT SECRET INTERLEUKIN-12 AND T...

MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE-CLEAVABLE SUBS...

MASKED CHIMERIC ANTIGEN RECEPTOR SPECIFIC TO TYROSINE-PROTEIN KINAS...

MATRIX METALLOPROTEASE-CLEAVABLE AND SERINE PROTEASE-CLEAVABLE SUBS...

ANTI-PTK7 IMMUNE CELL CANCER THERAPY

ANTI-LIV1 IMMUNE CELL CANCER THERAPY

MODIFIED ANTIBODY COMPOSITIONS, METHODS OF MAKING AND USING THEREOF

BISPECIFIC ANTI-CD3 ANTIBODIES, BISPECIFIC ACTIVATABLE ANTI-CD3 ANT...

ACTIVATABLE ANTIBODIES THAT BIND EPIDERMAL GROWTH FACTOR RECEPTOR A...

SYSTEMS AND METHODS FOR QUANTITATIVE PHARMACOLOGICAL MODELING OF AC...

ACTIVATABLE ANTIBODIES THAT BIND INTERLEUKIN-6 RECEPTOR AND METHODS...